{
    "clinical_study": {
        "@rank": "6767", 
        "arm_group": {
            "arm_group_label": "Radiation", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation\n      therapy following surgery may be effective in treating patients with phyllodes tumor of the\n      breast.\n\n      PURPOSE: This phase II trial is studying how well radiation therapy works after surgery in\n      treating women with phyllodes tumor of the breast."
        }, 
        "brief_title": "Radiation Therapy After Surgery in Treating Women With Phyllodes Tumor of the Breast", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Phyllodes Tumor"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the local recurrence rate in women with phyllodes tumors of the breast\n           previously treated with local excision with negative margins and are now treated with\n           adjuvant radiotherapy.\n\n        -  Determine the survival rate in patients treated with this regimen.\n\n      OUTLINE: Within 12 weeks after prior local excision or breast reexcision, patients undergo\n      adjuvant radiotherapy 5 days a week for a total of 28 treatments.\n\n      Patients are followed every 6 months for 10 years.\n\n      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within\n      approximately 6-7 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven phyllodes tumors of the breast with borderline or malignant\n             grade, defined as 1 of the following:\n\n               -  Borderline, defined as 5-9 mitoses/10 high power fields (HPF), pushing or\n                  infiltrating margins, 2+ atypia\n\n               -  Malignant, defined as 10 or more mitoses/10 HPF, predominantly infiltrating\n                  margins, usually 3+ atypia with occasional 2+ atypia\n\n          -  Must have been excised with breast-conserving resection\n\n               -  No positive margins\n\n          -  Local recurrence of a previously excised phyllodes tumor allowed if the recurrence is\n             in the area of the prior excision\n\n          -  No prior breast carcinoma or ductal carcinoma in situ in the ipsilateral breast\n\n          -  Hormone receptor status:\n\n               -  Not specified\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Sex:\n\n          -  Female\n\n        Menopausal status:\n\n          -  Not specified\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Not specified\n\n        Other:\n\n          -  Not pregnant\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy\n\n          -  Not specified\n\n        Chemotherapy\n\n          -  Not specified\n\n        Endocrine therapy\n\n          -  Not specified\n\n        Radiotherapy\n\n          -  No prior radiotherapy to the ipsilateral breast\n\n        Surgery\n\n          -  See Disease Characteristics"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003404", 
            "org_study_id": "CDR0000066410", 
            "secondary_id": [
                "P30CA023108", 
                "DMS-9801", 
                "DMS-12752", 
                "NCI-V98-1442"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Radiation", 
                "intervention_name": "adjuvant therapy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Radiation", 
                "intervention_name": "radiation therapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "recurrent breast cancer", 
            "phyllodes tumor"
        ], 
        "lastchanged_date": "April 15, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/DMS-9801"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Lebanon", 
                    "country": "United States", 
                    "state": "New Hampshire", 
                    "zip": "03756-0002"
                }, 
                "name": "Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective Study of Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors", 
        "overall_official": {
            "affiliation": "Norris Cotton Cancer Center", 
            "last_name": "Richard J. Barth, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Local recurrence rate", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003404"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "19424757", 
            "citation": "Barth RJ Jr, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol. 2009 Aug;16(8):2288-94. Epub 2009 May 8."
        }, 
        "secondary_outcome": {
            "measure": "Survival rate", 
            "safety_issue": "No", 
            "time_frame": "10 years"
        }, 
        "source": "Dartmouth-Hitchcock Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Dartmouth-Hitchcock Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 1998", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }, 
    "geocoordinates": {
        "Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center": "43.642 -72.252"
    }
}